Skip to content
ChickenStockChickenStock
ResearchTBPH
Theravance Biopharma logo

Theravance Biopharma (TBPH) stock

NASDAQ

Latest earnings

SEC filings

Apr–Jun 2026(FY2026 Q2)

Revenue decreased 19.2% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Aug 11, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

34 SEC filings
  • Weiss Asset Management LPInsider · Sep 23, 2026Other7,457,060 shares · $126.8M
    Avg. price $170 shares held after
  • Miller AineSVP, DEV & HEAD OF IRE OFFICE · Sep 23, 2026Disposition to the issuer189,826 shares
    Show 2 price lots
    • 96,718 sharesValue not reported
    • 93,108 sharesValue not reported
  • O'Connor DonalRole not reported · Sep 23, 2026Disposition to the issuer80,213 shares
    Show 2 price lots
    • 74,204 sharesValue not reported
    • 6,009 sharesValue not reported
  • MITCHELL DEAN JRole not reported · Sep 23, 2026Disposition to the issuer97,213 shares
    Show 2 price lots
    • 91,204 sharesValue not reported
    • 6,009 sharesValue not reported
  • GRAY SUSANNAHRole not reported · Sep 23, 2026Disposition to the issuer48,146 shares
    Show 2 price lots
    • 42,137 sharesValue not reported
    • 6,009 sharesValue not reported
  • Smaldone Alsup LaurieRole not reported · Sep 23, 2026Disposition to the issuer80,989 shares
    Show 2 price lots
    • 74,980 sharesValue not reported
    • 6,009 sharesValue not reported
  • Winningham Rick ECHIEF EXECUTIVE OFFICER · Sep 23, 2026Disposition to the issuer1,726,989 shares
    Show 5 price lots
    • 1,382,272 sharesValue not reported
    • 151,875 sharesValue not reported
    • 76,875 sharesValue not reported
    • 23,400 sharesValue not reported
    • 92,567 sharesValue not reported
  • Sawaf AzizSVP & CHIEF FINANCIAL OFFICER · Sep 23, 2026Disposition to the issuer336,841 shares
    Show 3 price lots
    • 204,966 sharesValue not reported
    • 108,436 sharesValue not reported
    • 23,439 sharesValue not reported
  • Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY · Sep 23, 2026Disposition to the issuer355,168 shares
    Show 3 price lots
    • 223,917 sharesValue not reported
    • 107,812 sharesValue not reported
    • 23,439 sharesValue not reported
  • Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · Sep 23, 2026Disposition to the issuer213,476 shares
    Show 2 price lots
    • 124,414 sharesValue not reported
    • 89,062 sharesValue not reported
  • PAKIANATHAN DEEPIKARole not reported · Sep 23, 2026Disposition to the issuer64,074 shares
    Show 2 price lots
    • 58,065 sharesValue not reported
    • 6,009 sharesValue not reported
  • Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · Sep 15, 2026Open-market sale13,314 shares · $227K
    Avg. price $17.0342
    Show 3 price lots
    • 6,657 shares × $17.0342$113K
    • 3,329 shares × $17.0341$57K
    • 3,328 shares × $17.0343$57K
  • Winningham Rick ECHIEF EXECUTIVE OFFICER · Aug 20, 2026Shares withheld for taxes20,034 shares · $340K
    Avg. price $16.951,611,022 shares held after
  • Sawaf AzizSVP & CHIEF FINANCIAL OFFICER · Aug 20, 2026Shares withheld for taxes8,112 shares · $137K
    Avg. price $16.95336,841 shares held after
  • Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY · Aug 20, 2026Shares withheld for taxes7,952 shares · $135K
    Avg. price $16.95355,168 shares held after
  • Miller AineSVP, DEV & HEAD OF IRE OFFICE · Aug 20, 2026Shares withheld for taxes6,258 shares · $106K
    Avg. price $16.95189,826 shares held after
  • Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · Aug 20, 2026Shares withheld for taxes5,667 shares · $96K
    Avg. price $16.95226,790 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Theravance Biopharma (TBPH) stock information

NASDAQ

Theravance Biopharma (TBPH) is listed on NASDAQ. These figures are computed in-house from official filings and are reference information only.

Theravance Biopharma — frequently asked questions

Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.